CD47 and lung carcinoma: Additional functional and mechanistic studies are required to understand whether CD47 directly supports lung cancer therapy resistance, but these reports rationalize further investigation since CD47 blockade could be a relevant line of treatment for patients resistant to specific NSCLC treatment modalities.